In Vivo LncRNA Inhibition in Human Tumor Xenografts Using Antisense Locked Nucleic Acid GapmeRs.

Pengju Gong, Qingsong Hu, Ke Liang, Chunru Lin

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pengju GongDepartment of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Qingsong HuDepartment of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Ke LiangDepartment of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Chunru LinDepartment of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. clin2@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) have emerged as significant regulators of many physiological and pathological processes and play a key role in the onset and progression of a variety of diseases, including cancer. Currently, the functions of the majority of lncRNAs in carcinogenesis are still unclear. Functional characterization of specific lncRNAs is often challenging using the conventional RNA interference method, due to their specific and restricted subcellular localization. Antisense locked nucleic acid (LNA) GapmeRs, which induce RNase H1-mediated RNA cleavage, provide a promising strategy to knock down lncRNAs regardless of their intracellular localization. Here, we describe a protocol for suppressing the lncRNA BIN3 Intronic Transcript 1 (BIN3-IT1) in human breast cancer xenografts using Antisense LNA GapmeRs.

Indexed as

Breast NeoplasmsOligonucleotidesOligonucleotides, AntisenseRNA, Long NoncodingAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMiceRibonuclease HRNA InterferenceXenograft Model Antitumor Assayslocked nucleic acidOligonucleotidesOligonucleotides, AntisenseRibonuclease HRNA, Long NoncodingBIN3-IT1Breast cancerLNA GapmeRslncRNAncRNATumor xenografts

Identifiers

PMID42911497

DOI10.1016/j.ymthe.2017.06.002

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.